Pfizer released Phase 3 CREST trial results shows reduction of disease-related events in high-risk non-muscle invasive bladder cancer
In more than three decades, the first possible therapy breakthrough for BCG-naïve, high-risk non-muscle invasive bladder cancer has been the combination of BCG and sasanlimab, a subcutaneously administered PD-1 inhibitor.
